| Identification | Back Directory | [Name]
Nidanilimab | [CAS]
2171061-85-9 | [Synonyms]
Nidanilimab
Nadunolimab
Nadunolimab (anti-IL-1 RAcP)
Research Grade Nadunolimab(DHJ63401) |
| Hazard Information | Back Directory | [Uses]
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2]. | [in vivo]
Nidanilimab (CAN04; 10 mg/kg; i.p.; nude C57Bl/6 mice) increases the efficacy of Cisplatin (HY-17394)/Gemcitabine (HY-17026) and Carboplatin (HY-17393)/Gemcitabine (HY-17026), two commonly used platinum-based chemotherapies[1]. | Animal Model: | Nude C57Bl/6 mice with LU2503 NSCLC PDX model[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Displayed a significantly stronger anti-tumor effect compared to isotype control with chemotherapy. |
| [IC 50]
IL-1α; IL-1β | [References]
[1] Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.
[2] Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. DOI:10.1007/s00262-022-03277-3 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|